Global Irritable Bowel Syndrome (IBS) Therapeutics Industry
NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Irritable Bowel Syndrome (IBS) Therapeutics Industry
http://www.reportlinker.com/p0611068/Global-Irritable-Bowel-Syndrome-IBS-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_
This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 50 companies including many key and niche players such as Abbott Laboratories, Alimentary Health Limited, Edusa Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Lexicon Pharmaceuticals, Pharmos Corporation, Salix Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., and Tioga Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 5
Irritable Bowel Syndrome: A Primer 5
Market Analysis 5
World IBS Market to Witness Substantial Growth Despite of
Anticipated Slump in the GI Therapeutics Market 5
New Drug Launches to Drive the Growth of Highly Underserved
IBS Market in Developed Markets 6
Select Drugs in Late Stage Clinical Development 6
Linaclotide: One of the Most Promising Pipeline Drugs with
Substantial Market Potential 7
Irritable Bowel Syndrome Represents a Major Therapeutic
Challenge 7
Available IBS Drugs: Treating the Symptoms, Not the Cause 7
A Comparison of Current and Previous Treatment for IBS 7
Select Drugs/Therapeutics Available for IBS Treatment by
Symptom 8
Involvement of the Brain-Gut Axis Emphasized the Role of
Serotonin in IBS 8
Serotonin 5-HT Receptors Led the Drug Development Pipeline 8
Lack of Selectivity Hampers Predominance of 5-HT Receptor
Class of Drugs 8
List of 5-HT Class Drug Withdrawals/Trial Failures 9
Amitiza Led the IBS-C Market in 2008-2009, New Drug Launches
Likely to Affect Sales 9
Safety Concerns of Available Drugs and Low Rate of Diagnosis
Limit Market Growth 9
Growth Drivers 10
IBS Market is Presently Highly Fragmented, Generecized, and
Under Served 10
Drug Development Programs Drive Market Growth in Developed
Countries 10
Product Co-development, Commercialization, and Licensing
Agreements 11
Other Growth Drivers 11
High Prevalence 11
Variable Diagnostic Criteria and IBS Prevalence 12
Growing Awareness 12
Multiple Treatment Approaches Make Way for Complementary
Medicines 12
Need for Diagnostic Markers 13
Development of Novel Therapies 13
3. DISEASE OVERVIEW 14
Prevalence 14
Table 1: Prevalence of IBS in Select Countries/Regions of the
World (includes corresponding Graph/Chart) 14
Prevalence by Gender: Higher Prevalence in Women 15
Symptoms of IBS 15
Comorbidities Associated with IBS 15
Classification of IBS Based on Symptoms 16
Diarrhea-predominant IBS or IBS-D 16
Constipation-predominant IBS or IBS-C 16
Alternating or Mixed Type IBS 16
List of Select Conditions that could be Misdiagnosed as IBS 16
Select Tests Recommended to Rule out GI Disorders Other than IBS 17
What Causes Irritable Bowel Syndrome 17
The Function of the Colon 17
IBS and the Enteric Nervous System 17
The Brain-Gut Interaction 17
Direct Control 18
Indirect Control 18
Etiology of Irritable Bowel Syndrome 18
Chronic Anxiety Mediated Visceral Hyperalgesia 18
Serotonin 19
5HT3 and 5HT4 Receptors 19
Genetic Factors 19
Gastrointestinal Infections 20
The Intestinal Bacteria 20
Diagnosis of Irritable Bowel Syndrome 20
IBS Diagnostic Protocols 20
The Rome III Criteria for IBS Diagnosis 21
IBS Diagnosis in Children 22
The Manning Criteria for IBS Diagnosis 22
4. TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) 23
Current Treatment Scenario 23
Combination Therapies Offer Limited Efficacy and Short-Term
Relief 23
An Overview of Select Treatment and Therapies for Irritable
Bowel Syndrome 24
Select Drug Classes Available for IBS Treatment 24
Dietary Fiber 24
List of Select Commercially Packaged Fibers 24
Bulk-forming Laxatives 25
Osmotic laxatives 25
List of Select Osmotic Laxatives 25
Poorly Absorbed Ions 25
Poorly Absorbed Sugars 25
Stimulant laxatives 26
List of Select Stimulant Laxatives by Type 26
Derivatives of Diphenylmethane 26
Derivatives of Anthraquinones 26
Emollients 26
Anti-Diarrheals 26
Antidepressants 27
Scientific Data Supports the Use of Antidepressants in IBS 27
Tricyclics: Preferred Class of Antidepressants for Treating IBS 27
Side Effects of TCAs 28
Antispasmodic Agents 28
Anticholinergic Agents 28
List of Select Anticholionergics 29
Peppermint Oil and Direct Smooth Muscle Relaxants 29
List of Select Direct Smooth Muscle Relaxants 30
Alternative Therapies 30
Probiotics 30
What are probiotics? 30
Role of Probiotics 30
Potential Use of Probiotics in IBS Management 30
Data from Research and Clinical Studies 31
Herbal Remedies 31
Psychotherapy 31
Others 31
5. PRODUCT APPROVALS IN THE PAST 32
Lotronex 32
Zelnorm 32
Amitiza 32
BENTYL® (dicyclomine hydrochloride) 33
Colpermin 33
Irribow (Ramosetron Hydrochloride) 34
6. PIPELINE ANALYSIS 35
Linaclotide 35
LX1031 35
XIFAXAN® (Rifaximin) 35
ASIMADOLINE 36
Drugs' Early Stage Clinical Trials 36
Select IBS Drugs in Early Stages of Clinical Trials 36
Review of Pipeline Drugs in the Past (2006) 37
7. CLINICAL TRIALS 38
Synergy Pharmaceuticals to Conduct Phase II/III Trial of
Plecanatide 38
Almirall and Ironwood Achieve Success in Second Phase III
Trial of Linaclotide in IBS-C 38
Oxy-Powder Demonstrates Success in IBS Test 39
Ironwood and Forest Achieve Positive Results in Phase 3 Trial
of Linaclotide 39
VSL 3 Proves Effective for Children Suffering from IBS 39
Salix's Xifaxan (Rifaximin) Found Effective on Non-C IBS Symptom 40
Lexicon Concludes Phase II Clinical Trial of LX1031 40
Ocera Achieves Positive Result in Phase 2 Proof-of-Concept
Trial of AST-120 40
Pharmos Achieves Positive Results in Phase 2b IBS Trial 41
Order-Made Souyaku to Commence IBS Drug Trials in the UK 42
8. RECENT INDUSTRY ACTIVITY 43
Tioga Receives Fast Track Status for Asimadoline in IBS-D 43
Canadian Institut Rosell Extends Partnership with Probi 43
Achieve Clinical Research Commences Clinical Trials for IBS 43
Wild Partners with Sterling Technology 44
AMRI Proposes New Drug For Irritable Bowel Syndrome 44
Salix Obtains FDA's Filing and Priority Review Approval for
XIFAXAN550 in Non-C IBS 44
Soligenix Receives US Patent for Beclomethasone Dipropionate
for IBS Treatment 45
Meda Takes Over Norgine's Over-the-Counter Drugs 45
Tioga Reaches Agreement with FDA For Phase 3 Trials Of
Asimadoline 45
Sucampo Files 'Demand for Arbitration' Against Takeda 46
Abbott Takes Over Solvay Pharmaceuticals 46
SK Holdings Obtains IND Approval from FDA for YKP10811 47
MicroDose Takes Over Epix's Portfolio of Compounds 47
PPD Inks Agreement with Janssen Pharmaceutica 47
Warner Chilcott Takes Over P&G's Global Branded Prescription
Pharmaceutical Business 48
Abbott Acquires Solvay's Pharmaceutical Business 48
Tioga and Ono Ink Licensing Agreement for IBS Drug Development 48
Lexicon Reacquires Joint Venture Rights from Symphony 49
Ironwood Enters into Partnership with Almirall 49
Pawfect Foods Takes Over Synergy Pharmaceuticals 49
Tioga and US FDA Agree on SPA for Phase 3 Efficacy Protocols
of Asimadoline in IBS-D 50
Sucampo Obtains FDA Approval for AMITIZA for IBS-C in Adult Women 50
Apex and Dynogen Dissolve Merger Agreement 51
Rose Pharma and Eli Lily Ink Licensing Agreement Pertaining to
Compound for IBS Treatment 51
Napo and Trine Terminate License Agreement for Crofelemer 52
9. PRODUCT INRODUCTIONS/INNOVATIONS 53
Cedars-Sinai Medical Center Introduces Rifaximin for IBS Patients 53
Lesaffre Introduces Probiotic Yeast to Treat Intestinal
Discomfort 53
Lifeway Foods Launches BioKefir Range of Probiotic Drinks 53
Mayo Clinic Discovers Novel Genetic Variants in Serotonin Genes 54
Jarrow Formulas® to Introduce Ideal Bowel Support 299v® 54
Buscopan Launches Online Interactive Resource for IBS Patient 54
Chongqing Fortune Introduces Traditional Chinese Medicine 55
Alimentary Health to Introduce New Probiotic Treatment 55
Alimentary Health to Launch IBS Treatment 55
Astellas Pharma Introduces Irribow for Irritable Bowel Syndrome 55
10. FOCUS ON SELECT PLAYERS 56
Abbott Laboratories (US) 56
Alimentary Health Limited (Ireland) 56
Edusa Pharmaceuticals (US) 56
Ironwood Pharmaceuticals, Inc. (US) 57
Forest Laboratories, Inc. (US) 57
Lexicon Pharmaceuticals (US) 57
Pharmos Corporation (US) 58
Salix Pharmaceuticals, Inc. (US) 59
Sucampo Pharmaceuticals, Inc. (US) 59
Tioga Pharmaceuticals, Inc. (US) 59
11. GLOBAL MARKET PERSPECTIVE 61
Table 2: World Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome (IBS) by Geographic Region - US,
Japan, Europe, Rest of World Market Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) 61
Table 3: World Historic Review for Irritable Bowel Syndrome
(IBS) by Geographic Region - US, Japan, Europe, and Rest of
World Market Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 62
Table 4: World 15-Year Perspective for Irritable Bowel
Syndrome (IBS) by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe, and Rest of World for
Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 63
12. THE UNITED STATES 64
A.Market Analysis 64
An Overview 64
Prevalence of IBS-C in the US 64
US Leads the Global IBS Drug Development Scenario 64
High Unmet Needs Characterize the IBS Market 65
New Drugs Releases Likely to Drive Market Growth in the Near
Future 65
Irritable Bowel Syndrome: Key Facts 65
Drugs Approved for Use in IBS Treatment 66
Amitiza 66
Zelnorm 66
Lotronex 66
Strategic Corporate Developments 67
Focus on Select Major Players 76
Abbott Laboratories (US) 76
Edusa Pharmaceuticals (US) 76
Ironwood Pharmaceuticals, Inc. (US) 76
Forest Laboratories, Inc. (US) 77
Lexicon Pharmaceuticals (US) 77
Pharmos Corporation (US) 78
Salix Pharmaceuticals, Inc. (US) 78
Sucampo Pharmaceuticals, Inc. (US) 79
Tioga Pharmaceuticals, Inc. (US) 79
B.Market Analytics 80
Table 5: The US Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 80
Table 6: The US Historic Review for Irritable Bowel Syndrome
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 80
13. JAPAN 81
A.Market Analysis 81
Strategic Corporate Development 81
Product Introductions/Innovation 81
B.Market Analytics 82
Table 7: Japanese Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 82
Table 8: Japanese Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 82
14. EUROPE 83
Market Analysis 83
Table 9: European Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome (IBS) by Geographic Region -
France, Germany, Italy, UK, Spain, Russia, and Rest of
Europe Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 83
Table 10: European Historic Review for Irritable Bowel
Syndrome (IBS) by Geographic Region - France, Germany,
Italy, UK, Spain, Russia, and Rest of Europe Market
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 84
Table 11: European 15-Year Perspective for RNA Interference
Application by Geographic Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, Spain, Russia,
and Rest of Europe for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 85
14a. FRANCE 86
Market Analysis 86
Table 12: French Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 86
Table 13: French Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 86
14b. GERMANY 87
Market Analysis 87
Table 14: German Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 87
Table 15: German Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 87
14c. ITALY 88
Market Analysis 88
Table 16: Italian Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 88
Table 17: Italian Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 88
14d. THE UNITED KINGDOM 89
A.Market Analysis 89
Product Introductions/Innovation 89
B.Market Analytics 89
Table 18: The UK Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 89
Table 19: The UK Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 90
14e. SPAIN 91
A.Market Analysis 91
Strategic Corporate Development 91
B.Market Analytics 92
Table 20: Spanish Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 92
Table 21: Spanish Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 92
14f. RUSSIA 93
Market Analysis 93
Table 22: Russian Recent Past, Current & Future Analysis for
Irritable Bowel Syndrome Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 93
Table 23: Russian Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 93
14g. REST OF EUROPE 94
A.Market Analysis 94
Strategic Corporate Developments 94
Product Introductions/Innovations 95
Focus on Select Key Player 96
Alimentary Health Limited (Ireland) 96
B.Market Analytics 97
Table 24: Rest of European Recent Past, Current & Future
Analysis for Irritable Bowel Syndrome Market Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 97
Table 25: Rest of European Historic Review for Irritable
Bowel Syndrome Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 97
15. REST OF WORLD 98
A.Market Analysis 98
Strategic Corporate Developments 98
Product Introductions/Innovation 99
B.Market Analytics 99
Table 26: Rest of World Recent Past, Current & Future
Analysis for Irritable Bowel Syndrome Market Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 99
Table 27: Rest of World Historic Review for Irritable Bowel
Syndrome Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 100
COMPETITIVE LANDSCAPE
Total Companies Profiled: 50 (including Divisions/Subsidiaries - 51)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 27
Canada 1
Japan 5
Europe 16
France 2
Germany 1
The United Kingdom 3
Italy 2
Spain 1
Rest of Europe 7
Asia-Pacific (Excluding Japan) 2
------------------------------------------
To order this report:
Drug and Medication Industry: Global Irritable Bowel Syndrome (IBS) Therapeutics Industry
Drug and Medication Business News
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article